Loading...
•
Dec 31, 2024
BioLife Q4 2024 Earnings Report
BioLife Solutions reported Q4 2024 results with strong revenue growth, improved margins, and reduced losses.
Key Takeaways
BioLife Solutions posted $22.7 million in revenue for Q4 2024, a 31% increase YoY. The company improved its gross margin to 60% GAAP (63% non-GAAP). Net loss narrowed to $2.0 million, while non-GAAP adjusted EBITDA was $4.0 million. The Cell Processing platform led growth with a 37% YoY revenue increase.
Total revenue grew 31% YoY to $22.7 million.
Cell Processing platform revenue increased 37% YoY to $20.3 million.
Gross margin improved to 60% GAAP, 63% non-GAAP.
Net loss reduced to $2.0 million from $7.2 million YoY.
BioLife
BioLife
BioLife Revenue by Segment
Revenue by Segment
Cell Processing platform Revenue
CapyFin.comevo and Thaw platform Revenue
CapyFin.com Forward Guidance
BioLife Solutions expects total revenue growth of 16-20% in 2025, driven by an 18-21% increase in the Cell Processing platform. The company anticipates maintaining strong gross margins and further reducing net losses.
Positive Outlook
- Projected revenue growth of 16-20% in 2025.
- Cell Processing platform expected to grow 18-21%.
- Gross margin to remain in the low 60% range.
- Adjusted EBITDA margin expected to expand.
- Increased cross-selling opportunities in biopreservation.
Challenges Ahead
- Continued net losses expected, though reduced.
- Operating loss still a concern despite improvement.
- Evo & Thaw platform growth expected to be modest (3-15%).
- Macroeconomic risks could impact revenue projections.
- Potential challenges in integrating divested assets.
Revenue & Expenses
Visualization of income flow from segment revenue to net income